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Regional perturbation of gene 
transcription is associated with 
intrachromosomal rearrangements 
and gene fusion transcripts in high 
grade ovarian cancer
paul M. Krzyzanowski1, Fabrice sircoulomb2, Fouad Yousif1, Josee Normand2,3, Jose La Rose2, 
Kyle e. Francis2, Fernando suarez2, tim Beck  4, John D. Mcpherson1,5, Lincoln D. stein1,6 & 
Robert K. Rottapel1,2
Genomic rearrangements are a hallmark of cancer biology and progression, allowing cells to rapidly 
transform through alterations in regulatory structures, changes in expression patterns, reprogramming 
of signaling pathways, and creation of novel transcripts via gene fusion events. though functional gene 
fusions encoding oncogenic proteins are the most dramatic outcomes of genomic rearrangements, 
we investigated the relationship between rearrangements evidenced by fusion transcripts and local 
expression changes in cancer using transcriptome data alone. 9,953 gene fusion predictions from 418 
primary serious ovarian cancer tumors were analyzed, identifying depletions of gene fusion breakpoints 
within coding regions of fused genes as well as an N-terminal enrichment of breakpoints within 
fused genes. We identified 48 genes with significant fusion-associated upregulation and furthermore 
demonstrate that significant regional overexpression of intact genes in patient transcriptomes occurs 
within 1 megabase of 78 novel gene fusions that function as central markers of these regions. We reveal 
that cancer transcriptomes select for gene fusions that preserve protein and protein domain coding 
potential. the association of gene fusion transcripts with neighboring gene overexpression supports 
rearrangements as mechanism through which cancer cells remodel their transcriptomes and identifies a 
new way to utilize gene fusions as indicators of regional expression changes in diseased cells with only 
transcriptomic data.
High grade serous ovarian cancer (HGSOC) is the second most common gynecological cancer and the most 
aggressive form of ovarian cancer1. HGSOC accounts for just 3% of all cancers in women, but is among the most 
lethal with a five year survival rate of only 20% and an overall mortality rate of 70%2. HGSOC is a disease of the 
damaged genome, characterized by widespread copy number alterations, a high frequency of TP53 mutations, 
but a paucity of dominant acting oncogenes3. In addition to chromatin damage surveillance defects due to TP53 
inactivation, HGSOC has a high frequency of inactivating mutations in other DNA damage repair pathways; 
it has been estimated that somatic alterations in BRCA1/2 and other Homologous Recombination Deficiency 
(HRD) genes may affect a total of 50% of HGSOC patients4,5. HGSOC is characterized with gains and losses of 
chromosome arms or entire chromosomes, and is amongst the most genomically unstable tumors of those that 
have been studied to date with a median 33% of the genome undergoing copy number alterations6. In addition, 
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a recent pan-cancer survey of whole genomes revealed that inter- and intra-chromosomal rearrangements are 
common in HGSOC, with an average of 261 genomic breakpoint events per sample7. Extensive chromosomal 
disruption has been associated with poor prognosis8, presumably due to the ability of genetically unstable cells 
to develop resistance to chemotherapy. High rates of chemoresistance may also be a reflection of the high levels 
of intratumoral genetic heterogeneity that is a hallmark of this cancer9. Because of the centrality of HGSOC’s 
genomic instability to its biology and clinical behavior, understanding the consequences of its genomic instability 
is essential to developing more effective biomarkers and therapeutic targets.
Relevance of gene fusions to ovarian cancer. The high level of genomic instability in HGSOC creates a 
fertile environment for the acquisition of fusion genes which can create neomorphic cancer drivers through the 
creation of novel domain combinations10. Intact domains in expressed protein fusions, in turn, can be selectively 
targeted11,12.
We sought to elucidate how expressed gene fusion events in HGSOC tumors might contribute to the trans-
formed state. We demonstrate that in contrast to the traditional model of positive selection for fusion transcripts 
generating novel proteins, the majority of the fusion transcripts detected do not result in in-frame fusion tran-
scripts, and that a subset of genes involved in fusion events instead exhibit transcriptional upregulation. We fur-
ther identify a novel phenomenon in which expressed fusion events are frequently associated with perturbation in 
gene expression in the neighborhood of the fusion event, an effect that can extend up to a megabase from the site 
of rearrangement, consistent with other studies linking more comprehensive genomic data such as whole exome 
sequencing13, Single Nucleotide Polymorphism (SNP) array data14, or whole genome sequencing15 with altered 
expression of nearby genes. Our study utilizes transcriptome data alone to demonstrate remodeling of the tran-
scriptome in HGSOC through gene fusion events that may contribute to the overall fitness of the evolving tumor.
Results
expressed fusion transcripts are ubiquitous in ovarian cancer. To characterize the landscape of 
expressed fusion transcripts, 420 HGSOC primary transcriptomes from The Cancer Genome Atlas (TCGA) pro-
ject were analyzed using defuse, a package for prediction fusion transcripts from RNA sequencing (RNA-seq) 
data16. Analysis of 418 out of 420 transcriptomes were completed successfully, yielding 38,043 raw fusion predic-
tions. Events also predicted using normal ovarian fallopian tube secretory epithelial cell samples were considered 
false positives and removed from the dataset (See Methods), leaving 9,953 fusion predictions (Supplementary 
Table 1). The number of expressed fusion events per tumor ranged from 1 to 111, with a median burden of 21 
fusion events per case (Interquartile Range (IQR) = 14–30) (Fig. 1A). This set of predictions was used throughout 
this study.
To supplement this information, we performed RNA-seq on a set of 42 commonly used ovarian cancer cell 
lines. These lines included both serous (n = 33) and clear cell (n = 6) carcinomas, as well as cell lines of other cellu-
lar origins. Applying the same fusion prediction and filtering methods as used for the TCGA primaries, we made 
3,037 raw fusion predictions, yielding 1,866 high confidence fusion transcripts after filtering (Supplementary 
Table 2). The fusion burden in cell lines was higher than in the primary tumors, with a median 38 chimeric tran-
scripts expressed per cell line (range = 5–123, IQR = 23–60). The difference may be explained by sampling bias 
related to differences in clonality between pure populations of cultured cell lines and heterogeneous primaries, 
where putative fusion expressing subclones may be present in small fractions which may reduce fusion transcript 
abundance below limits of detection. Primary tumors in ovarian cancer are typically a mixture of tumor and 
stromal cells with median stromal proportions of 50%17.
Mutational profile of ovarian fusion events in TCGA. We analyzed the structural features of this set 
of fusion transcripts (Fig. 1). Approximately 33% of detected fusions involved adjacent genes, which were pre-
dominantly classified as read-through transcripts (Fig. 1A). Mechanisms capable of generating read-through 
transcripts include rearrangements of genomic DNA, deletions of intergenic regions and mutations impacting 
transcriptional termination-events. The abundance of fusions involving adjacent genes in primary tumors (33%) 
is lower than the rate originally observed in ovarian cancer cell lines by McPherson et al. (68%, 1741/2540)16 and 
in the Australian Ovarian Cancer Study (AOCS) data (63%, 2050/3279), suggesting that either primary ovarian 
samples experience events that disrupt transcriptional termination less frequently than cell lines, or that a subset 
of fusion events are present at low abundance due to tumor heterogeneity and therefore not detected at a compa-
rable level of sensitivity. Cell lines had higher rates of predicted read-through transcripts (54%; Fig. 1A) than the 
primary tumors, although still lower than previously reported in the literature.
One of the most striking features of both the primary and cell line data was the high observed rate of intra-
chromosomal fusions (70.8%; Fig. 1A). To determine the enrichment level of these events, the fusion generation 
process was modeled as a stochastic process of chromosome breakage and repair, leading to the observation that 
this rate was 14-fold higher in the primary tumor than would be expected (Permutation test P < 10−5). The rate of 
intrachromosomal fusion events was even higher among the sequenced ovarian cell lines (85.4%; Permutation test 
P < 10−5). These results contrast with the 11% intrachromosomal rate of breakpoints reported by ChimerDB for 
all types of biological samples18. In addition, ovarian cancer cell lines exhibited a higher proportion of breakpoints 
within coding regions than in primary tumor samples (Two-sided 4-sample proportionality test P-value < 10−15, 
Fig. 1B) and were enriched in breakpoints within the 5′-UTRs of the 3′ fusion gene partners (Two-sided 2-sample 
proportionality test P-value = <10−15).
Somatic copy number alterations (CNAs) are a known mechanism through which tumors can control dosage 
of tumor suppressors and oncogenes. We investigated the relationship between these events and fusions using 
TCGA data computed with GISTIC, a method for identifying somatic copy-number alterations (Fig. 1C)19. When 
copy number states for genes involved in fusions were compared both low and high level amplifications were 
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found to be more frequently associated with fusions than with the background distribution of copy number levels, 
(Permutation Test, P < 1 × 10−6), confirming the previously-identified association of copy number events with 
chromosomal rearrangements8. However, our results indicate that the emergence of expressed fusion transcripts 
is not solely limited to regions of copy number gain.
Finally, we investigated whether the wide range of fusion burdens observed in ovarian patients were related 
to molecular subtypes (differentiated; immunoreactive; mesenchymal; and proliferative) as assigned by Verhaak 
et al. using CLOVAR, a single-sample gene set enrichment analysis (ssGSEA) classification approach20. Tumors 
classified as immunoreactive or proliferative tended to carry higher levels of expressed fusions compared to dif-
ferentiated or mesenchymal cases (Fig. 1D). The enrichment for these subtypes was statistically significant in the 
highest decile of fusion burden (Fig. 1E, Fisher’s Exact Test, P = 5 × 10−3), suggesting that immunoreactive and 
proliferative subtypes of ovarian tumors have higher rates of genomic rearrangements.
Gene fusions are enriched in N-terminal domains. Oncogenic fusion genes frequently coopt signaling 
proteins through truncation of their autoinhibitory domains as seen with ALK, ROS or RET fusions21. In these 
gene fusions, the secondary partner proteins typically participate in a passive role. In other cases, secondary 
partner proteins can create neomorphic functions of fusion oncogenes through the addition of subcellular local-
ization sequences or dimerization domains of the primary fusion partner, as in forced homotypic dimerizations 
of RARα22. Thus, the need for driver gene domains to remain intact suggests that breakpoints might be biased 
towards the 5′ or 3′ end of the original coding transcript.
We first investigated whether bias for or against breakpoint position was detectable in each major region of 
mRNAs (Fig. 2A). We observed that fusion transcripts were significantly enriched in breakpoints residing in 
the 5′ or 3′ UTR regions of one or both participating transcripts (Fig. 2A,B, P < 10−4 by permutation test) and a 
significant depletion in breakpoint frequency within coding regions (P < 10−4 by permutation test). These obser-
vations suggest selection against fusion transcripts encoding neomorphic proteins, possibly directed towards 
a reduction in the creation of novel immunogenic proteins, which would be created through novel peptide 
sequences encoded across fusion junctions in RNA. Though immunogenic proteins can come from both in-frame 
and out-of-frame fusion proteins, frameshifted proteins should have a higher likelihood of being immunogenic 
through the production of novel amino acid sequences. To test this, we examined whether tumors with high 
Figure 1. Characteristics of chimeric transcripts in ovarian cancer, in transcriptomes derived from TCGA 
primary tumors and ovarian cell lines. (A) Rearrangement classifications associated with fusion events, in TCGA 
primary transcriptomes and ovarian cancer cell lines. (B) Profiles of cDNA positions associated with expressed 
fusion transcripts in TCGA primaries. (C) Copy number status associated with evidence of TCGA fusion 
transcripts. (D) Density plots of fusion counts per tumor, separated by TCGA subgroups. (E) Proportions of 
OVCA subtypes vs expressed fusion load.
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and low proportions of out-of-frame fusions differed in regard to evidence of T-cell infiltration using a T-cell 
transcriptional signature (CD3D; CD3E; CD3G; CD6; SH2D1A; TRAT1)23, expecting to observe clustering of 
samples with high proportions of out-of-frame fusions according to this signature. However, we observed no 
clustering of tumors with high versus low burdens of out-of-frame fusion transcripts when using this signature 
(data not shown). These data suggest that evasion of immune selection pressure does not contribute to the paucity 
of frame-shifted fusion events.
Next, we tested for positional bias within the coding regions of genes involved in fusions. For example, if 
positive selection exists for fusions joining mostly intact coding regions of participating genes, we expected 
to observe an enrichment of breakpoints near the N- and C-termini of coding regions. Indeed, we found that 
TCGA ovarian fusion genes are enriched in breakpoints within the C-terminal region of coding sequences 
(P-value = 0.028, two-sample Kolmogorov-Smirnov (KS) test; Fig. 2C), but not the N-terminal portion (data not 
shown). Interestingly, the lack of enrichment within the N-terminus of coding regions may be due to the already 
high expected rate of breakpoints in this region, which is likely due to the 5′-bias observed in introns of eukary-
otic genomes24,25. Together, these observations argue for the selection of events that lead to transcripts encoding 
fusion proteins with a predominantly intact, and at least partially functional, protein coding genes.
the presence of fusion transcripts mark regions of dysregulated gene expression. Gene fusion 
events involved ‘promoter swapping’ often increase the expression of partner genes with otherwise low expression 
Figure 2. Gene fusion breakpoint locations within protein coding transcripts. (A) Expected distributions of 
cDNA breakpoint positions according to a random genomic breakage model. Red thresholds indicate observed 
positions. (B) Numerical data for A. (C) Normalized density plot illustrating observed breakpoint positions 
within cDNAs (bar plot) vs expected distribution (ribbon plot) with enrichment within C-terminal breakpoints 
of the CDS (star; Permutation test P < 10−4).
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levels26,27. In addition to promoter swapping, genomic rearrangements can bring enhancers into new regions 
of the genome, which can alter the transcriptional landscape. We hypothesized that if a generalized process of 
rearranging active regulatory elements in ovarian cancer cells exists, at least one gene partner in ovarian fusion 
transcripts should frequently be identified to be highly active in normal ovarian tissues.
To test this, we investigated whether genes associated with detected ovarian fusions were enriched in highly 
expressed ovarian tissue genes defined by GTEx. GTEx ovarian genes were ranked by expression level and the 
top n highly expressed genes were considered ‘active’. Statistical enrichment for these highly expressed genes was 
observed for all sets with at least 200 genes (Cumulative hypergeometric test P < 10−6 in all cases). These results 
indicate that ovarian cancer related gene fusions preferentially involve genes normally expressed at high levels in 
ovarian tissues.
Next, we sought to identify genes that exhibit significant expression differences between samples with or 
without detected fusion transcripts in the same gene. The TCGA primary ovarian tumor transcriptomes 
yielded 48 genes with this property (Table 1 and Supplementary Table S4), with several known genes exhibiting 
fusion-associated expression increases at a statistically significant level (Fig. 3). No genes with fusion-associated 
downregulation were identified, despite using a two-sided Wilcoxon test analysis. A notable gene with elevated 
expression levels correlated with fusion transcripts is MUC16/CA125, which occurred in 20 TCGA primaries 
(Fig. 4; Supplementary Table S5). Elevated serum CA125 is correlated with shorter overall survival among ovarian 
cancers28. CA125 fusion-positive primary tumors express the antigen transcript at levels in the upper quartiles of 
expression when all TCGA transcriptomes are considered. Interestingly, a MUC16 fusion (MUC16-OR7G2) was 
detected in only one cell line transcriptome (OVCAR3) (Supplementary Table S2).
These results indicate that the presence of fusion transcripts for certain genes is associated with expression 
changes of the genes directly involved in the fusion events. Though RNA-seq data alone cannot distinguish among 
expression changes arising due to promoter swapping/trapping, rearrangement of regulatory sequences in DNA, 
or another mechanism altogether, we hypothesized that regional overexpression is a general property linked to 
fusion expression. In this model, ovarian cancer cells with dormant genes are recruited to regions of activated 
transcription without addressing whether chimeric transcripts are a cause or effect of the rearrangement event.
To test this hypothesis, we identified genes in a two megabase window centered on each gene involved in a 
fusion event in the TCGA ovarian data set. These central genes are called ‘anchor genes’. For each anchor gene, we 
compared the expression level of neighboring genes in TCGA primaries expressing the fusion transcript to those 
that did not. We found a consistent increase in expression of genes on both sides of anchor genes in primaries that 
express anchor gene fusions (Fig. 5A). This pattern disappeared when the labels of anchor gene fusion status was 
randomized (Fig. 5B). These results indicate that the presence of anchor gene fusion transcripts acts as a marker 
of possible upregulation of nearby genes, an effect that extends to at least one megabase in each direction from the 
chimeric anchor gene transcript.
Finally, we identified 37 genes in the TCGA data set that were dysregulated specifically when a fusion was 
detected in one of 78 nearby anchor genes (Fig. 5C and Supplementary Table S6). These associated genes were 
typically upregulated and consist of a wide repertoire of known cancer associated genes, including ERCC4, 
DICER1, BCR, R-spondin 4 (RSPO4), INSL3, ELK3, and IDH1. Dysregulated genes exhibiting fusion associated 
fold changes greater than 2.13 (>90th percentile of all changes) were analyzed for enrichment using g:Profiler29, 
identifying enrichment in the transport of immune response modulators (RAB17, PIGR), peptidyl-serine phos-
phorylation (WNT5A, MAST3, TCL1A/B, PRKAA1, CHEK2), and serine/threonine protein kinase activities 
(BCR, MAST3, PRKAA1, CDK18, DYRK3, RIPK4, CHEK2). Together, these results suggest that selection for 
regionally upregulated genes in the neighborhoods of structural rearrangement events targets a small number of 
pathways that are associated with cancer cell fitness.
Discussion
High-grade serous ovarian cancer has long been known to be a disease characterized by genomic instability and 
structural variation30,31. Our data indicates that all four known serous ovarian cancer subtypes consistently exploit 
this instability to generate chimeric transcripts, making gene fusions a common aberration in HGSOC.
The large set of gene fusion predictions developed in this study allowed us to examine several characteristics 
of expressed fusions to infer factors that contribute to fusion creation. Fusion transcripts in HGSOC generally 
arise through intrachromosomal rearrangements suggesting that localized events, such as tandem duplications, 
dominate their creation. At the levels of individual genes it appears that biological pressures influence breakpoint 
positions. In contrast to a simple model in which gene fusion breakpoints occur with uniform probability across 
genes, fusions from primary tumor transcriptomes were found to arise from breakpoints that tend to occur in 
UTRs, while breakpoints in coding regions are biased to minimize disruptions to encoded proteins or protein 
domains (Fig. 2). These results suggest that both ovarian primary samples and cell lines exhibit strong bias against 
rearrangements that destroy protein coding potential of fusion transcripts.
In addition, the contrast between TCGA primary transcriptomes and cell line observations suggests that there 
is in vivo selection in primary tumors against the generation of fusion transcripts disruption protein coding 
regions, which could be an effect of selection against events that enhance immunogenicity through the crea-
tion neo-antigens. This idea is supported by our observation that cell lines, which are propagated in vitro in 
the absence of immunological surveillance, have higher rates of breakpoints in coding regions than primaries 
(Fig. 1B). Since breakpoints within coding sequences shuffle protein domains to create novel oncogenic pro-
teins, they also can enhance immunogenicity by creating neo-antigens, as has been previously shown to occur in 
cancer patients with high somatic mutational loads32. Conversely, it is possible that there is positive selection for 
alterations that change the expression level of one of the genes involved in the fusion without changing its protein 
coding potential. For example, breakpoints within untranslated regions, which increase the expression of fitness 
genes could be selected for by evolving cancer cells. Although these events would not be predicted to encode novel 
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proteins with neomorphic properties, they offer an efficient mechanism to place existing coding sequences under 
the control of novel promoters while reducing the chance of inducing an anti-tumor immune response, suggest-
ing promoter swapping events as a simple fusion event to increase cell fitness. Indeed, the observed enrichment 
of UTRs in our data suggests that shuffling of regulatory element(s) into apposition with newly associated coding 
regions is a broadly used mechanism by cancer cells to rewire the expression regulation of genes using structural 
Genes Description q-value Fold Change
AQP6 aquaporin 6 2.30E-08 8.91
DAPL1 death associated protein like 1 7.82E-08 6.94
VPREB3 pre-B lymphocyte 3 1.00E-07 2.16
INSL3 insulin like 3 1.96E-06 3.71
KISS1 KiSS-1 metastasis-suppressor 5.90E-05 3.73
AQP5 aquaporin 5 1.30E-04 3.67
C1orf186 chromosome 1 open reading frame 186 1.59E-04 1.80
C22orf31 chromosome 22 open reading frame 31 1.59E-04 15.28
TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) 1.59E-04 9.12
KCTD1 potassium channel tetramerization domain containing 1 1.90E-04 1.66
HKR1 HKR1, GLI-Kruppel zinc finger family member 2.20E-04 1.36
KIAA1683 KIAA1683 2.39E-04 4.13
CRYGC crystallin gamma C 2.56E-04 126.49
ZNF732 zinc finger protein 732 5.28E-04 2.64
KREMEN1 kringle containing transmembrane protein 1 5.39E-04 2.88
WNT10A wingless-type MMTV integration site family member 10A 5.40E-04 2.79
DIO3 deiodinase, iodothyronine, type III 5.76E-04 26.20
C2orf48 chromosome 2 open reading frame 48 6.74E-04 2.60
FGF12 fibroblast growth factor 12 7.37E-04 2.53
GOLT1A golgi transport 1A 8.46E-04 2.22
DAND5 DAN domain family member 5, BMP antagonist 9.66E-04 9.91
RRM2 ribonucleotide reductase M2 9.87E-04 1.81
LRRC69 leucine rich repeat containing 69 1.20E-03 7.85
ATP5I ATP synthase membrane subunit e 1.24E-03 2.01
C7 complement component 7 1.33E-03 10.87
ARID3C AT-rich interaction domain 3C 1.33E-03 15.54
BACE2 beta-site APP-cleaving enzyme 2 1.64E-03 2.09
COL6A3 collagen, type VI, alpha 3 2.13E-03 6.51
IGLL5 immunoglobulin lambda-like polypeptide 5 2.28E-03 7.15
SHISA9 shisa family member 9 2.53E-03 8.50
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 2.53E-03 4.04
DEFB126 defensin beta 126 2.66E-03 11.54
CHCHD10 coiled-coil-helix-coiled-coil-helix domain containing 10 2.70E-03 1.55
MFSD7 major facilitator superfamily domain containing 7 2.70E-03 1.80
JAK3 Janus kinase 3 4.29E-03 1.63
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 4.31E-03 2.56
IRX5 iroquois homeobox 5 5.36E-03 30.66
SIX4 SIX homeobox 4 5.48E-03 2.07
CCDC120 coiled-coil domain containing 120 5.51E-03 3.05
C2orf74 chromosome 2 open reading frame 74 6.34E-03 3.13
KLHL23 kelch like family member 23 6.34E-03 3.78
SLC29A1 solute carrier family 29 (equilibrative nucleoside transporter), member 1 7.38E-03 2.34
MSN moesin 7.57E-03 1.45
MUC16 mucin 16, cell surface associated 7.68E-03 2.35
KCNIP3 potassium voltage-gated channel interacting protein 3 7.74E-03 5.60
PARD3 par-3 family cell polarity regulator 9.01E-03 1.57
GLTPD2 glycolipid transfer protein domain containing 2 9.01E-03 7.07
NAA15 N(alpha)-acetyltransferase 15, NatA auxiliary subunit 9.82E-03 1.38
Table 1. Genes significantly upregulated with positive fusion status. Q-values represent FDR corrected p-values 
of fusion-positive versus fusion-negative expression levels (two-sided Wilcoxon test). Fold change of fusion-
positive versus fusion-negative expression levels are shown.
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rearrangements between 20 kilobases downstream and 100 kilobases upstream of affected genes, events that have 
been reported across 20 cancer types33. By using expressed transcripts as evidence of structural rearrangement, 
our study extends the effect of expression dysregulation to a megabase centered on the fused gene.
Our observation of megabase-scale localized upregulation of genes in the presence of anchoring gene fusion 
events is consistent with the findings reported by the Pan-Cancer Analysis of Whole Genomes network, which 
found a pattern of increased gene expression in the neighborhood of rearrangement breakpoints across a broad 
range of cancers7. A suggested mechanism for this phenomenon was interruption of chromatin loops via disrup-
tion of topologically-associating domains. The regional dysregulation centered around expressed gene fusions 
potentially introduces a novel role for fusion transcripts. Chromosomal rearrangements which cause of gene 
fusions are frequent in human tumors especially highly aneuploidy tumors. However, only a minority of these 
events are necessarily functional resulting in driver genetic alterations. Chromosomal rearrangements can lead to 
multiple perturbations within the genome, some of which may be selected for, and others, which may be neutral. 
Our results provide evidence that some expressed fusion transcripts may be selected for their ability to rewire 
the transcriptional landscape in the region of the fusion rather than for the enhanced fitness conferred by fusion 
product itself.
Together, our results demonstrate a potential use for detected fusion transcripts in the interpretation of altered 
cancer transcriptomes as a signal of underlying structural changes in the genome. We have shown evidence of 
clustering of overexpressed genes in the neighborhood of some fusions suggesting that heritable genomic rear-
rangement events contribute to the overexpression of genes in the cluster. The significance of this finding is that 
coordinated expression changes amongst clustered genes is a common evolutionary feature, for example in both 
normal development (Hox genes) and also in the evolution of malignancy in cancer cells (HSP1 regulation of 
genes such as NDRG2 and TPD5234). The presence of fusions in cancer transcriptomes are an indicator that 
nearby gene expression changes should be analyzed carefully for evidence of co-regulation, either by bioinformat-
ics approaches or co-analysis of features in genomic DNA.
Figure 3. Selected genes with expression changes significantly correlated with their fusion status in primary 
ovarian cancer tumors. Expression levels (FPKM) shown on y-axis with fusion status presented on x-axis.
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The identification of gene fusions which alter the transcription of gene ensembles may inform possible thera-
peutic modalities, as their expression is specific to diseased cells and their detection implies that cancerous cells 
exist with a bulk sample. Therefore, gene fusions can function as a flag that evidence of a cell clone carrying a rear-
rangement exists, genes associated with these clusters can offer a wide variety of known actionable targets in can-
cer treatments. For example, we observed that PLCB1 fusions were associated with overexpression of R-spondins. 
Inhibition of the Wnt pathway may be efficacious in triple negative breast cancers overexpressing R-spondins35, a 
therapeutic relationship that should be explored in HGSOC demonstrating the PLCB1 fusion or high R-spondin 
levels for other mechanistic reasons.
Conclusions
Our analyses identified positional biases in the breakpoint locations of fused genes. Gene fusion breakpoints 
within 5′-UTRs and 3′-UTRs are enriched to avoid disruptions of coding regions and breakpoints within cod-
ing regions exhibit breakpoints enriched in N-terminal proximal breakpoints. We demonstrate that significant 
regional overexpression of intact genes in patient transcriptomes can occur within 1 megabase of novel gene 
fusions, identifying a previously unrecognized mechanism through which cancer cells remodel their transcrip-
tomes and identifying a new way to utilize gene fusions as an indicator of regional expression changes in diseased 
cells. In summary, we have identified a novel class of gene fusions that perturb the expression of nearby genes that 
may contribute to the phenotype of HGSOC and establish a new analytical paradigm for analyzing the cancer 
transcriptome.
Methods
sequencing. RNA from ovarian cancer cell lines was extracted using the RNAeasy Plus kit (Qiagen) yielding 
RNA samples with RIN numbers (Agilent Bioanalyzer) of 8.0 or greater. Sample libraries were prepared using 
the TruSeq Stranded mRNA preparation kit (Illumina) and run on Illumina HiSeq2000 instruments generating 
2 × 101bp reads at a target library depth of >100 million reads per sample.
Figure 4. High levels of MUC16 are associated with fusion status. (A) Tumors with detected MUC16 fusion 
transcripts exhibit significantly higher MUC16 expression levels (Wilcox q-value = 0.008). Breakpoint 
distribution of MUC16 fusion events in primary ovarian transcriptomes, with classifications as outgoing 
(MUC16 N-terminal; red) or incoming (MUC16 C-terminal; blue). Mapping on to NM_024690 is shown.
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Data sets. TCGA Ovarian Data for 420 transcriptomes in distribution set phs000178.v7.p6.c1 were obtained 
under an approved Data Access Request from the National Center for Biotechnology Information Genotypes 
and Phenotypes Database (NCBI dbGaP). Picard (v1.56) was used to regenerate fastq files from BAM files down-
loaded from dbGap prior to bioinformatic analysis. Ovarian cancer cell line data is available from the NCBI 
BioProject portal (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA369618 and 
described further in36.
Transcriptomes for seven normal ovarian fallopian tube secretory epithelial cell samples from the Australian 
Ovarian Cancer Study (AOCS) (AOCS172–178)4 were analyzed with defuse (v0.6.1) to compile a list of fusion 
predictions that were likely to be false positives.
Expression Data Analysis. Transcriptomes were aligned using Tophat 2.0.3/bowtie 1 with default settings 
and coverage search turned off. Expression values were computed from the alignments with Cufflinks 2.0.2 with 
bias and multi-read correction parameters enabled using the UCSC hg19 gene model to produce FPKM values.
Gene Fusion predictions. Defuse v0.6.116 was used to predict fusion transcripts from paired fastq files 
in a parallelized compute environment utilizing Sun Grid Engine and compute nodes with at least 48 gigabytes 
of available memory for each defuse process and a hg19 based defuse reference dataset. Supporting software 
included samtools (v0.1.18), bowtie (v.0.12.7), R (v3.0.0), and gmap (v2013-07-20). Defuse predictions for TCGA 
and cell line transcriptomes with classifier probabilities greater than or equal to the threshold set using ovarian 
samples (0.81) by McPherson et al. and not present in the set of predictions from ovarian fallopian tube secretory 
epithelial cell samples were used for further analysis. Enrichment statistics on gene fusion features were calculated 
using a random model that assumes a uniform level of recombination across the entire genomic space.
subtype classification of transcriptomes. Transcriptome subtypes were assigned according to the 
CLOVAR serous ovarian cystadenocarcinoma signatures and the ssGSEA approach previously published20. TCGA 
Figure 5. Fusions act as markers of localized expression dysregulation. (A) Fusion correlated fold changes 
of genes in the proximity of fusion genes. Figure illustrates aggregated fold change data for all genes within 1 
megabase windows of fusion anchor gene, which lie at the central coordinate (distance = 0). Expected range 
of fold change (ribbon plot) computed using loess smoothing. (B) Identical figure but post-randomization of 
TCGA expression data and gene fusion status. (C) Circos plot indicating selected fusion genes (black), fusion 
associated dysregulated genes (blue), and ratio of observed vs. expected fusion frequencies (red barplot) across 
the human genome. Chromosomes 1–22, X, Y presented sequentially in clockwise order from the 12 O’clock 
position.
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subtypes were reclassified using the 489 TCGA samples expression table (‘TCGA_489_UE.gct’) obtained from 
tcga-data.nci.nih.gov. Probe set level expression values were collapsed to gene symbols using the HG-U133A chip 
definition file (ftp://ftp.broadinstitute.org/pub/gsea/annotations/HG_U133A.chip) prior to scoring subtype signa-
ture activation. A reimplemented version of single sample Gene Set Enrichment Analysis (ssGSEA) according to the 
protocol in Verhaak et al. was used to classify cell lines into subtypes. Briefly, normalized enrichment scores were 
calculated by determining enrichment scores for 1,000 randomly permuted gene lists and computing the mean value 
of expected raw scores for these permutations. Recalculated raw ssGSEA scores were verified to be correlated across 
all TCGA tumors correlated each within subtype signature (Data not shown). ssGSEA scores were then computed 
for cell lines using RNA-seq based expression data to assign each sample to a molecular subtype.
Data Availability
Transcriptome data for ovarian cancer cell lines is available from the NCBI BioProject portal (https://www.ncbi.
nlm.nih.gov/bioproject/) under accession number PRJNA480486. Other data sets are publically available; see 
Methods for details.
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